To predict whether these gene set enrichments may be related to Siglec‐XII activation of Shp2 signaling, we performed the same analysis on gene expression profiles of cancer cell lines that were found to be either dependent on Shp2 or independent of Shp2 in the development of resistance to MEK inhibition.41 The gene discussed is MAP2K7; the disease is cancer.